Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2017

View Archived Issues

Astellas reflects on accomplishments of fourth quarter of fiscal 2016

Roche reports key milestones of first quarter 2017

Daiichi Sankyo invests in manufacturing capabilities to support ADC pipeline

ENCORE 601 trial expands to include colorectal cancer cohort

Propanc Biopharma completes 28-day, repeat-dose toxicity study for PRP

Immune Pharmaceuticals restructures to focus on inflammatory disease and dermatology

European Commission approves Darzalex in combination therapy for multiple myeloma

Sorrento's TNK Therapeutics closes acquisition of Virttu Biologics

SkQ1 ophthalmic solution improves visual acuity in patients with Leber's hereditary optic neuropathy

FDA grants accelerated approval to Imfinzi for previously treated bladder cancer

Urumin, an anti-influenza virucide with efficacy in drug-resistant H1 influenza strains

Shire licenses rights to P-321 for ophthalmic indications

Phase III results for brexpiprazole to treat agitation related to Alzheimer's-type dementia

MSD K.K. seeks Japanese approval of Keytruda for locally advanced or metastatic urothelial cancer

FDA approves Rydapt for patients with newly diagnosed AML with FLT3 mutation

European Commission approves Opdivo for squamous cell cancer of the head and neck

Cerecor reports proof-of-concept data on CERC-501 in treatment-resistant depression

Daiichi Sankyo initiates phase I study of DS-3201b for AML and ALL

FDA grants accelerated approval to Alunbrig for ALK-positive NSCLC

Trial finds urolithin A safe in healthy elderly subjects

Neurotrope reports phase II topline results for bryostatin 1 in moderate to severe Alzheimer's

ZoptEC phase III study of Zoptrex in endometrial cancer does not meet primary endpoint

Jiangsu Nhwaluokang Pharmaceutical Research & Development patents etomidate derivatives

Pfizer's novel EZH2 inhibitor PF-6821497 selected for clinical development

Almirall discovers TRPA1 antagonists

Hetero Research Foundation identifies antiviral agents

NHWD-870 is a promising novel BET family bromodomain inhibitor against a broad spectrum of cancers

Bristol-Myers Squibb presents PD-L1/PD-1 and/or PD-L1/CD80 interaction inhibitors

GlaxoSmithKline divulges BRD4 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.